Opinion
Video
Author(s):
This study highlights the safety of mHSPC drugs in black men, supported by both trial data and real-world evidence.
Safety Data from Multiple Sources
Key Themes:
Key Points for Physicians:
Notable Insights: The convergence of evidence from clinical trials and real-world data strengthens confidence in safety conclusions despite relatively small sample sizes in individual studies.
Clinical Significance: The combination of clinical trial data and real-world evidence provides a comprehensive safety profile supporting the use of darolutamide in Black men with metastatic hormone-sensitive prostate cancer.